Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2020 August;111(4) > Minerva Medica 2020 August;111(4):315-23

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Medica 2020 August;111(4):315-23

DOI: 10.23736/S0026-4806.20.06205-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Safety and performance of everolimus-eluting stents comprising of biodegradable polymers with ultrathin stent platforms

Sudheer V. BOLINERA 1, Vemuri R. THARAKNATH 1, Sanivarapu S. REDDY 1, Raghava S. POLAVARAPU 1 , Anurag POLAVARAPU 1, Naren POLAVARAPU 1, Sravanthi BYRAPANENI 1, Sirichandana GANGASANI 1, Meghana CHILUKURI 2, Vijaya PAMIDIMUKKALA 1

1 Heart and Brain Center, Lalitha Super Specialties Hospital, Kothapet, Guntur, India; 2 Mahatma Gandhi Memorial Hospital, Warangal, India



BACKGROUND: The registry investigated clinical outcomes after 12 months of implantation of ultra-thin strut (60 µm) biodegradable polymer-coated Tetrilimus everolimus-eluting stents (EES; Sahajanand Medical Technologies Pvt. Ltd., Surat, India) in patients with atherosclerotic coronary lesions. Additionally, sub-group analysis was performed to evaluate outcomes of ultra-long (44/48 mm) Tetrilimus EES in patients with long lesions.
METHODS: This was an observational, single-center, single-arm and investigator-initiated retrospective registry. In this all-comers registry, patients who underwent implantation of Tetrilimus EES for treatment of coronary artery disease during routine clinical practice between February-2016 and August-2016 at tertiary care center of India were included. Primary endpoint was occurrence of any major adverse cardiac event (MACE) up to 12 months’ follow-up. MACE was a composite of cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR). Similar endpoints were observed in sub-group patients.
RESULTS: Total 766 stents were implanted to treat 695 lesions in 558 patients. Of treated lesions, 11.4% lesions were type B2 and 78.3% were type C lesions. In sub-group analysis of 143 patients, a total of 155 long coronary lesions were intervened successfully with only one stent been implanted per lesion. At 12 months’ follow-up, four (0.7%) cases of cardiac death, eight (1.4%) of MI, and two (0.4%) of TLR were reported, resulting in a 2.5% rate of MACE. The MACE rate was 2.8% in sub-group patients.
CONCLUSIONS: Twelve months’ clinical data demonstrated favorable safety and excellent performance of Tetrilimus EES in high-risk patients and complex coronary lesions in routine clinical practice and also in patients with ultra-long lesions.


KEY WORDS: Biopolymers; Everolimus; Drug-eluting stents; Percutaneous coronary intervention

top of page